The goal of the Hermans Laboratory is to investigate immune-based strategies to prevent or treat disease.
The use of vaccines to prevent infection has been a major advance in human health, but it is now clear that strategies to induce immune responses can also be used as a form of therapy to treat, rather than prevent, diseases. The Hermans Laboratory has spent several years studying the cellular interactions required to elicit effective immune responses, with the aim of developing novel vaccines and immunotherapies for prophylactic or therapeutic use. The focus has been on stimulating T-cells, a type of immune cell that can selectively kill infected or malignant cells.
The network of cellular interactions required to activate T cells includes dendritic cells, which provide the primary molecular signals needed to stimulate T cell function, and other less well-known cells, such as innate like T cells, that have the ability to influence the function of dendritic cells. Using this information, the Hermans Laboratory have worked closely with chemists to identify compounds that provoke the required sequence of cellular events to optimise T cell responses. This has led to new vaccine designs, including mRNA-based vaccines, and the development of drugs that can be combined with existing immunotherapies to improve treatment of cancer.
To conduct this work the Hermans Laboratory works closely with internationally renowned chemists and immunologists, and has close links with international groups to test new concepts in relevant models of infection and cancer.
Senior Research Officers: Kathryn Farrand, Ching Wen Tang
Research Officers: John Mamum, Gordon Zhao
PhD Students: Hannah Boswell, Kaitlin Buick, Jarem Wylie
- Development of mRNA vaccines for cancer and infectious disease
- Improving CAR T cell therapy for treatment of solid tumours
- Improving cancer immunotherapy with drugs that are activated in the low-oxygen environment of a tumour
New study opens doors for immunotherapies for prostate cancer
13 December 2021
Improving cancer immunotherapies through hypoxia-activated drugs
20 October 2020
Malaghan vaccine used in development of novel malaria treatment
1 July 2020
Marsden funding for CAR T-cell research into solid tumours
21 November 2019
Holz LE, Chua YC, de Menezes MN, Anderson RJ, Draper SL, Compton BJ, Chan STS, Mathew J, Li J, Kedzierski L, Wang Z, Beattie L, Enders MH, Ghilas S, May R, Steiner TM, Lange J, Fernandez-Ruiz D, Valencia-Hernandez AM, Osmond TL, Farrand KJ, Seneviratna R, Almeida CF, Tullett KM, Bertolino P, Bowen DG, Cozijnsen A, Mollard V, McFadden GI, Caminschi I, Lahoud MH, Kedzierska K, Turner SJ, Godfrey DI, Hermans IF, Painter GF, Heath WR (2020). Glycolipid-peptide vaccination induces liver-resident memory CD8+ T cells that protect against rodent malaria. Sci Immunol. 5(48):eaaz8035
Anderson RJ, Compton BJ, Tang C, Authier-Hall A, Hayman CM, Swinerd GW, Kowalczyk R, Harris P, Brimble MA, Larsen DS, Gasser O, Weinkove R, Hermans IF, Painter GF. (2015). NKT Cell-Dependent Glycolipid-Peptide Vaccines with Potent Anti-tumour Activity. Chem. Sci.
Anderson RJ, Tang C, Daniels NJ, Compton BJ, Hayman CM, Johnston KA, Knight DA, Gasser O, Poyntz HC, Ferguson PM, Larsen DS, Ronchese F, Painter GF, Hermans, IF. (2014). A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. Nat Chem Biol